{"id":86112,"date":"2021-04-21T11:27:12","date_gmt":"2021-04-21T14:27:12","guid":{"rendered":"https:\/\/iclos.global\/eng\/?post_type=product&#038;p=86112"},"modified":"2021-04-21T11:33:34","modified_gmt":"2021-04-21T14:33:34","slug":"usmal","status":"publish","type":"product","link":"https:\/\/iclos.global\/eng\/producto\/usmal\/","title":{"rendered":"Usmal"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row row_height_percent=\u00bb0&#8243; overlay_alpha=\u00bb50&#8243; gutter_size=\u00bb3&#8243; column_width_percent=\u00bb100&#8243; shift_y=\u00bb0&#8243; z_index=\u00bb0&#8243; el_class=\u00bbborro-en-producto\u00bb][vc_column width=\u00bb1\/1&#8243;][vc_column_text]<\/p>\n<h3>Principio activo: Rituximab<br \/>\nPresentaciones: 500 mg x vial<br \/>\n100 mg x vial<\/h3>\n<p>&nbsp;<\/p>\n<h4><\/h4>\n<p><strong>Mecanismo de acci\u00f3n y blancos moleculares (biol\u00f3gicos)<\/strong><\/p>\n<p>Rituximab es un anticuerpo monoclonal obtenido por ingenier\u00eda gen\u00e9tica que se une a la prote\u00edna CD20 presente en la superficie de la mayor\u00eda de los linfocitos pre-B, B y se expresa en m\u00e1s de 95% de los linfomas no Hodgkin de c\u00e9lulas B. La actividad antitumoral ocurre a trav\u00e9s de la citotoxicidad dependiente del complemento o de anticuerpos, y a trav\u00e9s del efecto citot\u00f3xico mediante el complejo ant\u00edgeno-anticuerpo.[\/vc_column_text][\/vc_column][\/vc_row][vc_row row_height_percent=\u00bb0&#8243; overlay_alpha=\u00bb50&#8243; gutter_size=\u00bb3&#8243; column_width_percent=\u00bb100&#8243; shift_y=\u00bb0&#8243; z_index=\u00bb0&#8243; el_class=\u00bbcatalogo-item\u00bb][vc_column width=\u00bb1\/1&#8243;][vc_row_inner][vc_column_inner width=\u00bb1\/1&#8243;][vc_empty_space empty_h=\u00bb0&#8243;][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner width=\u00bb5\/6&#8243;][vc_column_text][\/vc_column_text][\/vc_column_inner][vc_column_inner width=\u00bb1\/6&#8243;][vc_column_text]<img decoding=\"async\" class=\"alignnone wp-image-85422 size-full\" src=\"https:\/\/iclos.global\/eng\/wp-content\/uploads\/2020\/05\/logo-prod.png\" alt=\"\" width=\"128\" height=\"46\" \/>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<h3>Principio activo: Rituximab<br \/>\nPresentaciones: 500 mg x vial<br \/>\n100 mg x vial<\/h3>\n<p>&nbsp;<\/p>\n<h4><\/h4>\n<p><strong>Mecanismo de acci\u00f3n y blancos moleculares (biol\u00f3gicos)<\/strong><\/p>\n<p>Rituximab es un anticuerpo monoclonal obtenido por ingenier\u00eda gen\u00e9tica que se une a la prote\u00edna CD20 presente en la superficie de la mayor\u00eda de los linfocitos pre-B, B y se expresa en m\u00e1s de 95% de los linfomas no Hodgkin de c\u00e9lulas B. La actividad antitumoral ocurre a trav\u00e9s de la citotoxicidad dependiente del complemento o de anticuerpos, y a trav\u00e9s del efecto citot\u00f3xico mediante el complejo ant\u00edgeno-anticuerpo.<\/p>\n<p><strong>Indicaciones terap\u00e9uticas<\/strong><\/p>\n<p>En pacientes adultos para:<\/p>\n<ul>\n<li>Linfoma no Hodgkin (LNH)<\/li>\n<li>Leucemia linfoc\u00edtica cr\u00f3nica (LLC)<\/li>\n<li>Artritis reumatoide (AR)<\/li>\n<li>Granulomatosis con poliange\u00edtis o poliange\u00edtis microsc\u00f3pica<\/li>\n<\/ul>\n<p><strong>Aprobaciones y pautas (FDA; EMA; ASCO; ESMO)<\/strong><\/p>\n<p>Rituximab ha sido aprobado por EMA y FDA para las indicaciones anteriormente mencionadas.<\/p>\n<p><strong>Dosis y plan terap\u00e9utico<\/strong><\/p>\n<p>La dosis y el plan terap\u00e9utico depender\u00e1 de la indicaci\u00f3n.<br \/>\nDosis inicial recomendada: 375 mg\/m\u00b2 de superficie corporal v\u00eda IV<br \/>\nArtritis reumatoide: 1000mg v\u00eda IV<\/p>\n<p><em>Por m\u00e1s informaci\u00f3n ver la ficha t\u00e9cnica del producto.<\/em><\/p>\n","protected":false},"featured_media":86113,"template":"","meta":[],"product_cat":[125],"product_tag":[],"class_list":{"0":"post-86112","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-sin-categorizar","7":"pa_area-terapeutica-biotecnologicos","8":"pa_area-terapeutica-hemato-oncologia","9":"pa_nombre-usmal","10":"pa_principio-activo-rituximab","12":"first","13":"instock","14":"shipping-taxable","15":"product-type-simple"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Usmal - ICLOS<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/iclos.global\/eng\/producto\/usmal\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Usmal - ICLOS\" \/>\n<meta property=\"og:description\" content=\"Principio activo: Rituximab Presentaciones: 500 mg x vial 100 mg x vial &nbsp;  Mecanismo de acci\u00f3n y blancos moleculares (biol\u00f3gicos)  Rituximab es un anticuerpo monoclonal obtenido por ingenier\u00eda gen\u00e9tica que se une a la prote\u00edna CD20 presente en la superficie de la mayor\u00eda de los linfocitos pre-B, B y se expresa en m\u00e1s de 95% de los linfomas no Hodgkin de c\u00e9lulas B. La actividad antitumoral ocurre a trav\u00e9s de la citotoxicidad dependiente del complemento o de anticuerpos, y a trav\u00e9s del efecto citot\u00f3xico mediante el complejo ant\u00edgeno-anticuerpo.  Indicaciones terap\u00e9uticas  En pacientes adultos para:   Linfoma no Hodgkin (LNH)  Leucemia linfoc\u00edtica cr\u00f3nica (LLC)  Artritis reumatoide (AR)  Granulomatosis con poliange\u00edtis o poliange\u00edtis microsc\u00f3pica  Aprobaciones y pautas (FDA; EMA; ASCO; ESMO)  Rituximab ha sido aprobado por EMA y FDA para las indicaciones anteriormente mencionadas.  Dosis y plan terap\u00e9utico  La dosis y el plan terap\u00e9utico depender\u00e1 de la indicaci\u00f3n. Dosis inicial recomendada: 375 mg\/m\u00b2 de superficie corporal v\u00eda IV Artritis reumatoide: 1000mg v\u00eda IV  Por m\u00e1s informaci\u00f3n ver la ficha t\u00e9cnica del producto.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/iclos.global\/eng\/producto\/usmal\/\" \/>\n<meta property=\"og:site_name\" content=\"ICLOS\" \/>\n<meta property=\"article:modified_time\" content=\"2021-04-21T14:33:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/iclos.global\/eng\/wp-content\/uploads\/2021\/04\/usmal.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"600\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/iclos.global\/eng\/producto\/usmal\/\",\"url\":\"https:\/\/iclos.global\/eng\/producto\/usmal\/\",\"name\":\"Usmal - ICLOS\",\"isPartOf\":{\"@id\":\"https:\/\/iclos.global\/eng\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/iclos.global\/eng\/producto\/usmal\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/iclos.global\/eng\/producto\/usmal\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/iclos.global\/eng\/wp-content\/uploads\/2021\/04\/usmal.jpg\",\"datePublished\":\"2021-04-21T14:27:12+00:00\",\"dateModified\":\"2021-04-21T14:33:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/iclos.global\/eng\/producto\/usmal\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/iclos.global\/eng\/producto\/usmal\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/iclos.global\/eng\/producto\/usmal\/#primaryimage\",\"url\":\"https:\/\/iclos.global\/eng\/wp-content\/uploads\/2021\/04\/usmal.jpg\",\"contentUrl\":\"https:\/\/iclos.global\/eng\/wp-content\/uploads\/2021\/04\/usmal.jpg\",\"width\":600,\"height\":600},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/iclos.global\/eng\/producto\/usmal\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/iclos.global\/eng\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tienda\",\"item\":\"https:\/\/iclos.global\/eng\/tienda\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Usmal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/iclos.global\/eng\/#website\",\"url\":\"https:\/\/iclos.global\/eng\/\",\"name\":\"MEGALABS\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/iclos.global\/eng\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Usmal - ICLOS","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/iclos.global\/eng\/producto\/usmal\/","og_locale":"es_ES","og_type":"article","og_title":"Usmal - ICLOS","og_description":"Principio activo: Rituximab Presentaciones: 500 mg x vial 100 mg x vial &nbsp;  Mecanismo de acci\u00f3n y blancos moleculares (biol\u00f3gicos)  Rituximab es un anticuerpo monoclonal obtenido por ingenier\u00eda gen\u00e9tica que se une a la prote\u00edna CD20 presente en la superficie de la mayor\u00eda de los linfocitos pre-B, B y se expresa en m\u00e1s de 95% de los linfomas no Hodgkin de c\u00e9lulas B. La actividad antitumoral ocurre a trav\u00e9s de la citotoxicidad dependiente del complemento o de anticuerpos, y a trav\u00e9s del efecto citot\u00f3xico mediante el complejo ant\u00edgeno-anticuerpo.  Indicaciones terap\u00e9uticas  En pacientes adultos para:   Linfoma no Hodgkin (LNH)  Leucemia linfoc\u00edtica cr\u00f3nica (LLC)  Artritis reumatoide (AR)  Granulomatosis con poliange\u00edtis o poliange\u00edtis microsc\u00f3pica  Aprobaciones y pautas (FDA; EMA; ASCO; ESMO)  Rituximab ha sido aprobado por EMA y FDA para las indicaciones anteriormente mencionadas.  Dosis y plan terap\u00e9utico  La dosis y el plan terap\u00e9utico depender\u00e1 de la indicaci\u00f3n. Dosis inicial recomendada: 375 mg\/m\u00b2 de superficie corporal v\u00eda IV Artritis reumatoide: 1000mg v\u00eda IV  Por m\u00e1s informaci\u00f3n ver la ficha t\u00e9cnica del producto.","og_url":"https:\/\/iclos.global\/eng\/producto\/usmal\/","og_site_name":"ICLOS","article_modified_time":"2021-04-21T14:33:34+00:00","og_image":[{"width":600,"height":600,"url":"https:\/\/iclos.global\/eng\/wp-content\/uploads\/2021\/04\/usmal.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/iclos.global\/eng\/producto\/usmal\/","url":"https:\/\/iclos.global\/eng\/producto\/usmal\/","name":"Usmal - ICLOS","isPartOf":{"@id":"https:\/\/iclos.global\/eng\/#website"},"primaryImageOfPage":{"@id":"https:\/\/iclos.global\/eng\/producto\/usmal\/#primaryimage"},"image":{"@id":"https:\/\/iclos.global\/eng\/producto\/usmal\/#primaryimage"},"thumbnailUrl":"https:\/\/iclos.global\/eng\/wp-content\/uploads\/2021\/04\/usmal.jpg","datePublished":"2021-04-21T14:27:12+00:00","dateModified":"2021-04-21T14:33:34+00:00","breadcrumb":{"@id":"https:\/\/iclos.global\/eng\/producto\/usmal\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/iclos.global\/eng\/producto\/usmal\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/iclos.global\/eng\/producto\/usmal\/#primaryimage","url":"https:\/\/iclos.global\/eng\/wp-content\/uploads\/2021\/04\/usmal.jpg","contentUrl":"https:\/\/iclos.global\/eng\/wp-content\/uploads\/2021\/04\/usmal.jpg","width":600,"height":600},{"@type":"BreadcrumbList","@id":"https:\/\/iclos.global\/eng\/producto\/usmal\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/iclos.global\/eng\/"},{"@type":"ListItem","position":2,"name":"Tienda","item":"https:\/\/iclos.global\/eng\/tienda\/"},{"@type":"ListItem","position":3,"name":"Usmal"}]},{"@type":"WebSite","@id":"https:\/\/iclos.global\/eng\/#website","url":"https:\/\/iclos.global\/eng\/","name":"MEGALABS","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/iclos.global\/eng\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"}]}},"_links":{"self":[{"href":"https:\/\/iclos.global\/eng\/wp-json\/wp\/v2\/product\/86112","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/iclos.global\/eng\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/iclos.global\/eng\/wp-json\/wp\/v2\/types\/product"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/iclos.global\/eng\/wp-json\/wp\/v2\/media\/86113"}],"wp:attachment":[{"href":"https:\/\/iclos.global\/eng\/wp-json\/wp\/v2\/media?parent=86112"}],"wp:term":[{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/iclos.global\/eng\/wp-json\/wp\/v2\/product_cat?post=86112"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/iclos.global\/eng\/wp-json\/wp\/v2\/product_tag?post=86112"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}